Досліджується становлення світоглядних позицій та формування політичних поглядів І. Мазепи.Исследуется становление мировоззренческих позиций и формирование политических взглядов И. Мазепы.Formation world outlook positions and formation of political views of I. Mazepa is investigated

Altintas, I.

De Zan, E.

Haselberg, R.

Hennink, W.E.

Heukers, R.

Kok, R.J.

Pepermans, R.

Raghoenath, S.

Roovers, R.C.

Schiffelers, R.M.

van Bergen en Henegouwen, P.M.P.

The hepatocyte growth factor receptor (HGFR, c-Met or Met) is a receptor tyrosine kinase that is involved in embryogenesis, tissue regeneration and wound healing. Abnormal activation of this proto-oncogene product is implicated in the development, progression and metastasis of many cancers. Current therapies directed against Met, such as ligand- or, dimerization-blocking antibodies or kinase inhibitors, reduce tumor growth but hardly eradicate the tumor. In order to improve anti-Met therapy, we have designed a drug delivery system consisting of crosslinked albumin nanoparticles decorated with newly selected anti-Met nanobodies (anti-Met-NANAPs). The anti-Met NANAPs bound specifically to and were specifically taken up by Met-expressing cells and transported to lysosomes for degradation. Treatment of tumor cells with anti-Met NANAPs also resulted in downregulation of the total Met protein. This study shows that anti-Met NANAPs offer a potential system for lysosomal delivery of drugs into Met-positive tumor cells. © 2013 Elsevier Ltd

NARCIS 

Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles

The hepatocyte growth factor receptor (HGFR, c-Met or Met) is a receptor tyrosine kinase that is involved in embryogenesis, tissue regeneration and wound healing. Abnormal activation of this proto-oncogene product is implicated in the development, progression and metastasis of many cancers. Current therapies directed against Met, such as ligand- or, dimerization-blocking antibodies or kinase inhibitors, reduce tumor growth but hardly eradicate the tumor. In order to improve anti-Met therapy, we have designed a drug delivery system consisting of crosslinked albumin nanoparticles decorated with newly selected anti-Met nanobodies (anti-Met-NANAPs). The anti-Met NANAPs bound specifically to and were specifically taken up by Met-expressing cells and transported to lysosomes for degradation. Treatment of tumor cells with anti-Met NANAPs also resulted in downregulation of the total Met protein. This study shows that anti-Met NANAPs offer a potential system for lysosomal delivery of drugs into Met-positive tumor cells

Heukers, Raimond

Altintas, Isil

Raghoenath, Smiriti

De Zan, Erica

Pepermans, Richard

Roovers, Rob C.

Haselberg, Rob

Hennink, Wim E.

Schiffelers, Raymond M.

Kok, Robbert J.

Van Bergen en Henegouwen, Paul M P

Utrecht University Repository

Sub Drug delivery

UIPS - Utrecht Institute for Pharmaceutical Sciences

Sub Cell Biology

Sub Crystal and Structural Chemistry

Sub Biomolecular analysis

Sub General Pharmaceutics

Celbiologie

Гаврик, В.

Наукова електронна бібліотека періодичних видань НАН України (Vernadsky National Library of Ukraine)